
WHIM syndrome - Pipeline Insight, 2025
Description
DelveInsight’s, “WHIM syndrome – Pipeline Insight, 2025,” report provides comprehensive insights about companies and pipeline drugs in WHIM syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
WHIM syndrome: Overview
WHIM syndrome is a rare primary immunodeficiency disorder, which are disorders in which the body’s immune system does not function properly. WHIM is an acronym for some of the characteristic symptoms of the disorder – (w)arts, (h)ypogammaglobulinemia, (i)nfections, and (m)yelokathexis. Individuals with WHIM syndrome are more susceptible to potentially life-threatening bacterial infections. They are also predisposed to viral infections. Affected individuals are particularly susceptible to human papillomavirus (HPV), which can cause skin and genital warts and potentially lead to cancer. Affected individuals have extremely low levels of certain white blood cells (neutrophils) leading to a condition called neutropenia. In most patients, WHIM syndrome is caused by changes (mutations) in the CXCR4 gene. This mutation is inherited in an autosomal dominant pattern.
Symptoms
The symptoms of WHIM syndrome can vary greatly from one individual to another. Some individuals may have mild expression of the disorder and others may develop potentially life-threatening complications. Common infections in children with WHIM syndrome include recurrent middle ear infections (otitis media), infection of the skin and underlying tissue (cellulitis, impetigo, folliculitis, and abscess), bacterial pneumonia, sinusitis, painful infections of the joints (septic arthritis), dental cavities, and infection of the gums (periodontitis). Chronic infections can potentially cause additional symptoms.
Diagnosis
A diagnosis of WHIM syndrome is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests including genetic tests. A complete blood count will show low levels of neutrophils, or neutropenia, a variable degree of lymphopenia, and normal to low hemoglobin and platelet levels. Initial workups can also reveal hypogammaglobulinemia.
If WHIM syndrome is suspected based on initial tests, the surgical removal and microscopic examination of bone marrow tissue (bone marrow biopsy) may be performed. If this biopsy confirms myelokathexis, this is strongly suggestive of WHIM syndrome.
Treatment
Treatment of WHIM syndrome may include immunoglobulin replacement therapy, granulocyte colony stimulating factor (G-CSF), or granulocyte macrophage colony stimulating factor (GM-CSF), to bolster production and maturation of neutrophils and reduce the incidence of infection. Immunoglobulin therapy, whether administered intravenously (IVIG) or subcutaneously (SCIG), can treat hypogammaglobulinemia and help reduce the frequency of recurrent bacterial infections.
WHIM syndrome Emerging Drugs Chapters
This segment of the WHIM syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
WHIM syndrome Emerging Drugs
Further product details are provided in the report……..
WHIM syndrome: Therapeutic Assessment
This segment of the report provides insights about the different WHIM syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 1 +products under different phases of clinical development like
WHIM syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses WHIM syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging WHIM syndrome drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
WHIM syndrome: Overview
WHIM syndrome is a rare primary immunodeficiency disorder, which are disorders in which the body’s immune system does not function properly. WHIM is an acronym for some of the characteristic symptoms of the disorder – (w)arts, (h)ypogammaglobulinemia, (i)nfections, and (m)yelokathexis. Individuals with WHIM syndrome are more susceptible to potentially life-threatening bacterial infections. They are also predisposed to viral infections. Affected individuals are particularly susceptible to human papillomavirus (HPV), which can cause skin and genital warts and potentially lead to cancer. Affected individuals have extremely low levels of certain white blood cells (neutrophils) leading to a condition called neutropenia. In most patients, WHIM syndrome is caused by changes (mutations) in the CXCR4 gene. This mutation is inherited in an autosomal dominant pattern.
Symptoms
The symptoms of WHIM syndrome can vary greatly from one individual to another. Some individuals may have mild expression of the disorder and others may develop potentially life-threatening complications. Common infections in children with WHIM syndrome include recurrent middle ear infections (otitis media), infection of the skin and underlying tissue (cellulitis, impetigo, folliculitis, and abscess), bacterial pneumonia, sinusitis, painful infections of the joints (septic arthritis), dental cavities, and infection of the gums (periodontitis). Chronic infections can potentially cause additional symptoms.
Diagnosis
A diagnosis of WHIM syndrome is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests including genetic tests. A complete blood count will show low levels of neutrophils, or neutropenia, a variable degree of lymphopenia, and normal to low hemoglobin and platelet levels. Initial workups can also reveal hypogammaglobulinemia.
If WHIM syndrome is suspected based on initial tests, the surgical removal and microscopic examination of bone marrow tissue (bone marrow biopsy) may be performed. If this biopsy confirms myelokathexis, this is strongly suggestive of WHIM syndrome.
Treatment
Treatment of WHIM syndrome may include immunoglobulin replacement therapy, granulocyte colony stimulating factor (G-CSF), or granulocyte macrophage colony stimulating factor (GM-CSF), to bolster production and maturation of neutrophils and reduce the incidence of infection. Immunoglobulin therapy, whether administered intravenously (IVIG) or subcutaneously (SCIG), can treat hypogammaglobulinemia and help reduce the frequency of recurrent bacterial infections.
WHIM syndrome Emerging Drugs Chapters
This segment of the WHIM syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
WHIM syndrome Emerging Drugs
- Mavorixafor (X4P-001): X4 Pharmaceuticals
Further product details are provided in the report……..
WHIM syndrome: Therapeutic Assessment
This segment of the report provides insights about the different WHIM syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in WHIM syndrome
Phases
DelveInsight’s report covers around 1 +products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
WHIM syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses WHIM syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging WHIM syndrome drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence WHIM syndrome R&D. The therapies under development are focused on novel approaches to treat/improve WHIM syndrome.
- WHIM syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing WHIM syndrome drugs?
- How many WHIM syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of WHIM syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the WHIM syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for WHIM syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- X4 Pharmaceuticals
- X4P-001
Table of Contents
40 Pages
- Introduction
- Executive Summary
- WHIM syndrome: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- WHIM syndrome – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- WHIM syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- WHIM syndrome Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- X4P-001: X4 Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- WHIM syndrome Key Companies
- WHIM syndrome Key Products
- WHIM syndrome- Unmet Needs
- WHIM syndrome- Market Drivers and Barriers
- WHIM syndrome- Future Perspectives and Conclusion
- WHIM syndrome Analyst Views
- WHIM syndrome Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.